Singapore, May 1 -- Taiwan-based Formosa Pharmaceuticals, Inc. and the Singapore Eye Research Institute (SERI) have annoounced a strategic research collaboration to develop next-generation ophthalmic formulations.

This partnership will leverage Formosa's proprietary APNT(R) (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI's world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD.

The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability...